Neuromyelitis optica (NMO; Devic's disease) and its spectrum disorders are idiopathic inflammatory demyelinating diseases of the central nervous system (CNS) that mainly affect the optic nerves and spinal cord 1 . The hallmark of NMO pathology is the presence of necrotic spinal cord lesions involving both gray and white matter, often resulting in cavitation, as well as the presence of vascular hyalinization 2 . NMO and multiple sclerosis (MS) are currently considered different diseases since the description of NMO-IgG, a serum gamma immunoglobulin autoantibody that is a specific marker for NMO 3, 4 . NMO-IgG selectively binds to aquaporin-4 (AQP4) water channel, a component of the dystroglycan protein complex of astrocytic foot processes at the blood-brain barrier 5 . Its sensitivity and specificity for NMO diagnosis were confirmed in several studies and the presence of NMO-IgG is now one of the new diagnostic criteria for neuromyelitis optica 4 . NMO may represent the first example of a novel class of autoimmune channelopathy 5 . The clinical course of NMO is usually more severe than of MS. Within five years of onset, fifty percent of patients either lose functional vision in at least one eye or become unable to walk unassisted 6 . Detection of the autoantibody enables early diagnosis of NMO, before the presence of a full-blown clinical picture, allowing early initiation of appropriate immunosuppressive therapy. This is the first study of frequency of NMO-IgG in a series of Brazilian relapsing NMO patients.
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METHOD
Twenty-eight patients with NMO from the Center for Myelin Disorders of the Neurologic Clinic of São Paulo University School of Medicine, São Paulo, Brazil, were enrolled. All of them fulfilled the original criteria for diagnosis of NMO 6 . Demographic and clinical characteristics of patients included in our study are shown on Table 1 . Briefly, median age at onset of disease was 27 years (range 7-51), median time of follow-up was 8 years (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The mean time elapsed between optic neuritis and myelitis was 18 months (median 21; range 2-60), Kurtzke's Expanded Disease Severity Score on last visit was 6.0 (range 2-8).
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All patients presented with recurrent disease and were receiving azathioprine (3 mg/kg daily) when a blood sample was drawn for this study and sent to Mayo Clinic Rochester, Rochester, Minnesota, USA. Serum NMO-IgG was detected using the methodology described by Lennon et al. 3 at Mayo Clinic. All subjects or their legal responsible signed the Informed Consent Form, and the study was approved by the Institutional Review Board and conducted in compliance with the Declaration of Helsinki.
RESULTS
Serum NMO-IgG was detected in 18 (64.3%) of the 28 patients enrolled. Female to male ratio was 8.3:1 and 75% of patients were non-whites.
DISCUSSION
There are descriptions of the frequency of NMO-IgG in NMO patients in different populations 7 ( Table 2 ). The first publication included 102 North American patients with NMO or with high-risk syndromes for NMO (recurrent optic neuritis or longitudinally extensive transverse myelitis), and 12 Japanese patients with optic-spinal multiple sclerosis (OSMS). In that seminal paper the authors found sensitivity and specificity for NMO diagnosis of 73% and 91%, respectively 3 . In Japan, authors detected NMOIgG in more than half of OSMS patients (63% sensitivity) 8 , suggesting that NMO and OSMS could be the same entity.
The prevalence of NMO and MS varies significantly among different regions of the world 15, 16 . Such differences are due to variability in genetic susceptibility and environmental factors 17 . MS in North American individuals of European extraction is associated with human leukocyte antigen (HLA) DRB1*1501 (DR2), while Asian individuals with HLA DPB1*0501 have a higher risk for NMO. Interestingly, HLA DPB1*0501 is present in 60% of the normal people in Japan, but in less than 10% of the North American population [18] [19] [20] [21] .
In Brazil, HLA DQB1, DQA1 and DRB1 genotype variability according to ethnicity was analyzed 22 . The authors concluded that DQA1*0201-0301 alleles were associated with white Brazilian population and the DRB*1501 allele was present in European-Brazilians and DRB1*03-1503 in African-Brazilians; the DRB1*1501 allele confers an ethnicity-dependent MS susceptibility in European patients whereas DQB1*0602 allele confers genetic susceptibility regardless of ethnicity 22 . Maybe these findings could explain the higher prevalence of NMO in patients with African ancestry in virtue of ethnicity-dependent susceptibility. In our sample of 28 patients with NMO, 18 were seropositive for the NMO-IgG antibody, 15 of them African descents and only 3 European descents.
To our knowledge this is the first report on the frequency of NMO-IgG as a serological marker for NMO in Brazilian patients. In our series, among clinically defined NMO patients, NMO-IgG was positive in 64.3%. This seroprevalence is similar to that observed by others 3, 8 .
In a recent study 23 , multiple logistic analyses revealed that emergence of the anti-NMO-IgG antibody was positively associated with a higher relapse rate. Thus, this method can be a useful and reliable tool in NMO diagnosis and management in Brazilian patients, in spite of ethnical differences and genetic peculiarities of our population. We hope that early detection of NMO-IgG in Brazilian patients with NMO and high-risk syndromes for NMO assures prompt and appropriate therapy.
